Progenra, Inc.
271A Great Valley Parkway
Malvern
Pennsylvania
19355
United States
Tel: 610-644-6974
Fax: 610-644-4705
Website: http://www.progenra.com/
11 articles about Progenra, Inc.
-
Progenra Inc. Receives Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research and Drug Development
12/18/2018
Funding will support Progenra’s development of small molecules for treatment of Parkinson’s Disease
-
Progenra, Inc. Receives Second Immune Oncology Patent
5/11/2017
-
Progenra, Inc. Release: Biotech Discovers Novel Immune Oncology Drug
1/17/2017
-
Eminent Immuno-Oncologist, Dr. Wayne Hancock, Joins Progenra, Inc.’S Scientific Advisory Board
10/31/2014
-
Progenra, Inc.'s Novel USP7 Inhibitors are Shown to Exert Multiple Anti-Tumor Effects
10/8/2012
-
New Study Demonstrating Progenra, Inc.'s Novel Anti-Tumor Compound Overcome VELCADE® (bortezomib) Resistant Multiple Myeloma Cells
9/17/2012
-
New Study Demonstrating the Selectivity of Progenra, Inc.'s Novel Anti-Tumor Compound
11/28/2011
-
Progenra, Inc. and Tokyo Medical University Form Rheumatoid Arthritis Research Collaboration
10/24/2011
-
Progenra, Inc. and Ono Pharmaceutical Company, Ltd. Enter into Research Collaboration
10/11/2011
-
Progenra, Inc. Receives Approval of Novel Patent for Isopeptidase High Throughput Screening Platform
7/26/2010
-
LifeSensors Inc. Launches their Ubiquitin Pathway Enzymes Assay Kits Licensed from Progenra, Inc.
7/10/2009